Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2022-11-04

Clinical Trial Update: A Study to Assess the Safety and Efficacy of Etrasimod in Subjects With Moderate-to-Severe Atopic Dermatitis [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating safety and efficacy of etrasimod for moderate-to-severe atopic dermatitis has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Etrasimod (etrasimod)

Snippet

Sponsor: Arena Pharmaceuticals | Conditions: Atopic Dermatitis | Phase 2 | Status: COMPLETED | Results posted: 2022-11-04